Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

BACKGROUND: Chronic hepatitis C virus (HCV) infection is a significant medical burden in China, affecting more than 10 million persons. In clinical trials and real-world settings, treatment with ledipasvir/sofosbuvir in patients with genotype 1 HCV infection resulted in high sustained virologic resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Lai, Xie, Qing, Hou, Jin Lin, Tang, Hong, Ning, Qin, Cheng, Jun, Nan, Yuemin, Zhang, Lunli, Li, Jun, Jiang, Jianning, McNabb, Brian, Zhang, Fangqiu, Camus, Gregory, Mo, Hongmei, Osinusi, Anu, Brainard, Diana M., Gong, Guozhong, Mou, Zhuangbo, Wu, Shanming, Wang, Guiqiang, Hu, Peng, Gao, Yanhang, Jia, Jidong, Duan, Zhongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904238/
https://www.ncbi.nlm.nih.gov/pubmed/29637511
http://dx.doi.org/10.1007/s12072-018-9856-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904238/
https://www.ncbi.nlm.nih.gov/pubmed/29637511
http://dx.doi.org/10.1007/s12072-018-9856-z

Ejemplares similares